Patents Assigned to Aravive Biologics, Inc.
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 11136563
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 5, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, ARAVIVE BIOLOGICS, INC.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Antifibrotic activity of GAS6 inhibitor
    Patent number: 10876176
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 29, 2020
    Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • Antiviral activity of Gas6 inhibitor
    Patent number: 10137173
    Abstract: Compositions and methods are provided for treating viral infection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: November 27, 2018
    Assignee: Aravive Biologics, Inc.
    Inventor: Raymond Tabibiazar
  • Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
    Patent number: 9879061
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 30, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9822347
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 21, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson